Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
To lead the global Multiple Sclerosis movement to progress the quality of life of people affected by Multiple Sclerosis and to support better thoughtful of the treatment of MS by simplifying international cooperation between MS societies, the international research community and other investors. People affected by Multiple Sclerosis can live their best lives, restore what has been lost and end Multiple Sclerosis forever. Positive Results Announced from Clinical Trial of BAF-312 (Siponimod) in Secondary Progressive MS, According to a company press release, in a 60-month, phase III clinical trial involving 1,651 people with minor progressive Multiple Sclerosis, the experimental oral therapy siponimod met its primary endpoint of reducing the risk of disability progression compared with inactive placebo.
Read More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi